STOCK TITAN
  1. Home
  2. News
  3. ASLN

ASLAN Pharmaceuticals Ltd - ASLN STOCK NEWS

Welcome to our dedicated news page for ASLAN Pharmaceuticals (Ticker: ASLN), a resource for investors and traders seeking the latest updates and insights on ASLAN Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ASLAN Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ASLAN Pharmaceuticals's position in the market.

News
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
ASLAN Pharmaceuticals reports positive data from ongoing studies, including TREK-DX and FAST-AA, and receives a favorable patent opinion. Financially, the company shows a reduction in cash burn and completion of a direct offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.37%
Tags
earnings
-
News
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
Rhea-AI Summary
ASLAN Pharmaceutical (ASLN) to present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference, offering a virtual company presentation by CEO Carl Firth. Institutional investors and industry participants can register to listen to the presentation and schedule one-on-one meetings with ASLAN management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
conferences
-
News
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
Rhea-AI Summary
ASLAN Pharmaceuticals (ASLN) announces a registered direct offering and concurrent private placement of 5,000,000 American Depositary Shares at $1.00 per ADS, with additional unregistered warrants. This move aims to raise capital for the company's development of innovative treatments in the immunology field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-57.98%
Tags
offering
News
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
Rhea-AI Summary
ASLAN Pharmaceuticals initiates TREK-DX trial for eblasakimab in dupilumab-experienced AD patients, showing promising results. The study aims to target IL-13R effectively, potentially offering a new treatment option for AD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
160.8%
Tags
none
-
News
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
Rhea-AI Summary
ASLAN Pharmaceuticals announces positive translational data in a head-to-head study of eblasakimab and dupilumab for COPD treatment. Leading respiratory experts appointed as scientific advisors. New data shows eblasakimab outperformed dupilumab in improving airway function and bronchodilation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.03%
Tags
management
-
News
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
Rhea-AI Summary
ASLAN Pharmaceuticals secures new Composition of Matter Patent for farudodstat, extending patent protection until at least 2043. The patent would provide commercial exclusivity for the potential first-in-class treatment option for alopecia areata, strengthening the company's intellectual property.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.71%
Tags
none
News
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Rhea-AI Summary
ASLAN Pharmaceuticals (ASLN) received a notice from Nasdaq indicating non-compliance with the US$1.00 minimum bid price requirement. The company has 180 days to regain compliance or may face delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.1%
Tags
none
-
News
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
Rhea-AI Summary
ASLAN Pharmaceuticals (Nasdaq: ASLN) announces participation in upcoming conferences for January 2024, including the 13th Annual LifeSci Partners Corporate Access Event and Biotech Showcase in San Francisco, and Dermatology Summit at the Hyatt Regency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
none
-
News
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
Rhea-AI Summary
ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN) is advancing eblasakimab and farudodstat in Phase 2 testing, with promising results in atopic dermatitis and alopecia areata. The company is also broadening its business development collaborations and reducing cash burn for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
none
News
ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference
Rhea-AI Summary
ASLAN Pharmaceuticals (Nasdaq:ASLN) announced that Dr. Carl Firth, CEO, will participate in a fireside discussion at the Piper Sandler Healthcare Conference. The conference will be held in-person at the Lotte New York Palace Hotel from November 28 to 30, 2023. A replay of the discussion will be available on ASLAN’s website, and management will be available for one-on-one meetings with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Stock ASLN logo
ASLAN Pharmaceuticals Ltd

Nasdaq:ASLN

ASLN Rankings

#5307 Ranked by Market Cap
#4588 Ranked by Stock Gains
N/A Ranked by Dividends

ASLN Stock Data

11.13M
371.91M
0.05%
15.46%
0.52%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Cayman Islands
190 Elgin Avenue

About ASLN

aslan pharmaceuticals (aslan, 6497.tt) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. aslan targets diseases that are both highly prevalent in asia and orphan indications in the united states and europe. led by a senior management team with extensive experience in global and regional development and commercialization, aslan is headquartered in singapore and has offices in taiwan and china. aslan’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. aslan’s partners include array biopharma, bristol-myers squibb, almirall and csl.